Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label brentuximab vedotin monotherapy in front-line treatment of Hodgkin lymphoma and CD30-positive peripheral T-cell lymphoma in older or comorbid patients
2019-003982-17Phase 2Terminated
- Sponsor
- Seagen
- Start
- Nov 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin in Hodgkin lymphoma (HL) and peripheral T-cell lymphoma (PTCL), sponsored by Seagen. Primary endpoint: Overall response rate. Started Nov 2020; status: terminated.
02
Drugs
brentuximab vedotin
03
Conditions
Hodgkin lymphoma (HL)peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on 2019-003982-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003982-17.